Bariatric surgery and biological aging in Nantes patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Nantes Bariatric Surgery Cohort is an observational study enrolling 300 adults scheduled for bariatric surgery and following them over approximately 3.5 years. Participants have pre‑operative, peri‑operative, and post‑operative visits during which clinical measurements, questionnaires, blood tests, anthropometrics, and biocollections (including samples for microbiota and cellular analyses) are collected. The study will compare markers of biological age, adipocyte dysfunction, microbiota composition, and circadian/biological rhythms before and after surgery. Analyses will look for links between changes in those biological measures and changes in biological age.

Why it matters

Who can join: the full rules

Inclusion Criteria :

Individuals selected for bariatric surgery (starting the BC pathway within the Nantes University Hospital bariatric unit). Inclusion criteria are those of the Bariatric Surgery program.

* male or female, adult over 18 years of age
* BMI ≥ 35 kg/m2 with complication(s) or ≥ 40 kg/m2 with or without complication (the list of eligible complications is referenced in HAS 2024 recommendations). In the event of a change in access to bariatric surgery, this threshold could be revised without any substantial change to the protocol.
* having consented to their participation in the cohort
* participant affiliated to or benefiting from a social security scheme

Exclusion Criteria :

* Persons protected by law (guardianship or trusteeship) or deprived of their freedom,
* Pregnant women (contraindication to CB) or nursing mothers.

Where it's running

• Nantes University Hospital
  Nantes, Loire-Atlantique, France Recruiting

Study contacts

• Principal investigator: David JACOBI, PU-PH — Nantes University Hospital
• Study coordinator: David JACOBI, PU-PH
• Email: david.jacobi@chu-nantes.fr
• Phone: 33 2 53 48 27 09

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.